Remedium Capital Partners
Remedium Capital Partners reported 6 stocks worth $452M in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are ORKA (33.0%), SYRE (28.8%) and Apogee Therapeutics Inc (17.2%). Compared with Q1 2026, the fund opened new positions in CBIO, added to SYRE and sold out of CBIO.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  ORKA Oruka Therapeutics Inc | $149M | 33.0% | 1.6M | No change | 3 of 3 | |
| 2 |  SYRE Spyre Therapeutics Inc | $130M | 28.8% | 1.5M | +7,938 (+1%) | 3 of 3 | |
| 3 | APOGEE THERAPEUTICS INC | $77.9M | 17.2% | 587K | +3,100 (+1%) | 3 of 3 | |
| 4 | GALECTO INC | $53.2M | 11.8% | 2M | No change | 3 of 3 | |
| 5 |  JBIO Jade Biosciences Inc | $35.1M | 7.8% | 1.6M | No change | 3 of 3 | |
| 6 |  CBIO Crescent Biopharma Inc. | $6.5M | 1.4% | 361K | New position | 1 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CBIO Crescent Biopharma Inc. | $6.6M | 361K |
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 7, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Remedium Capital Partners 13F FAQ
What does Remedium Capital Partners own?
Remedium Capital Partners reported 6 stocks worth $452M in its 13F filing for Q2 2026, filed Aug 7, 2026. Its largest holdings are ORKA (33.0%), SYRE (28.8%) and Apogee Therapeutics Inc (17.2%). The table above lists every position in the filing (the top 10 without an account).
What did Remedium Capital Partners buy and sell in Q2 2026?
Compared with Q1 2026: 1 new positions, 2 added to, 0 trimmed and 1 sold out. New positions include CBIO. It sold all of CBIO.
When will Remedium Capital Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Remedium Capital Partners's portfolio worth?
The Q2 2026 filing reports $452M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.